Novartis released its 1998 Pharmacy Benefit Report, a compilation of 1997 pharmacy benefit facts and figures gathered by independent researchers and analysts.
Novartis Pharmaceutical Corp. released its 1998 Pharmacy Benefit Report, a compilation of 1997 pharmacy benefit facts and figures gathered by independent researchers and analysts.
The report, which relies on data gathered from 48 health maintenance organization pharmacy directors and IMS Health's "Retail Method-of-Payment Report," was compiled by means of electronic survey. It includes utilization and costs data for both the managed care and retail markets, HMO drug benefit design information and insight into forces that drive changes in pharmacy management.
Novartis selected drugs and classes for inclusion in the report. Therefore, not all classes and drugs were included in final data.
Key findings from the report include:
•Â In 1997, third-party payers accounted for 63% of prescription dollar volume, a 4.5% increase over 1996. Cash share fell from 29.3% of dollar volume in 1996 to 25% in 1997.
•Â The average annual number of retail prescriptions per U.S. resident increased to 8.5 prescriptions in 1997.
•Â The total HMO universe in 1997 expanded to 72.3 million members. Independent practice association plans captured 56.6% of total enrollment; 92.4% of those in managed care plans had access to a pharmacy benefit. Medications dispensed through those managed benefit plans (for the key classes and products included in the report) totaled 217.6 million prescriptions and generated managed care plan expenditures of $8.5 billion.
•Â HMOs surveyed reported spending an average $15.57 per member per month for an average 0.7 prescriptions.
•Â Generic products accounted for 44.6% of HMO prescriptions and 25% of drug expenditures.
•Â Antidepressants were the most prescribed class for HMOs with 369.8 prescriptions per 1,000 members and a per-member-per-year ranking second among all classes at $19.35.
•Â Gastrointestinal agents led HMO expenditures with a per-member-per-year cost of $19.88, ranking fourth in prescription volume with 252.9 prescriptions per 1,000 members.
•Â Antipsychotics, gastrointestinal agents and beta-agonists led all classes in Medicaid's share of total retail prescriptions at 46.7%, 14.6% and 14.6%, respectively.
Detailed data from the report can be accessed on Novartis' Internet site with an assigned password. For more information, call Novartis at (800) 456-4994. PR
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.